Freshfields conflict hands Links £702m CAT deal
Linklaters has scooped the lead advisory role on British pharmaceutical giant Astra Zeneca’s £702m offer for Cambridge Antibody Technology (CAT) after Freshfields Bruckhaus Deringer was conflicted out of the deal. Astra Zeneca instructed Linklaters instead of regular counsel Freshfields because the latter firm acted for Abbott Laboratories in its dispute, last year, with CAT over […]